glycine has been researched along with Alcoholism in 27 studies
Alcoholism: A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alcohol dependence is a heterogeneous disorder where several signalling systems play important roles." | 1.39 | Ghrelin receptor (GHS-R1A) antagonism suppresses both alcohol consumption and the alcohol deprivation effect in rats following long-term voluntary alcohol consumption. ( Engel, JA; Fredriksson, I; Jerlhag, E; Steensland, P; Suchankova, P, 2013) |
| "The patient developed local swelling, bullae and exuding wounds." | 1.39 | Severe adverse effects related to dermal exposure to a glyphosate-surfactant herbicide. ( Ebbehøj, NE; Juhl, A; Madsen, PV; Mariager, TP; Schmidt, B, 2013) |
| "The mechanisms involved in alcohol use disorders are complex." | 1.38 | Ghrelin receptor (GHS-R1A) antagonism suppresses both operant alcohol self-administration and high alcohol consumption in rats. ( Bartlett, SE; Engel, JA; Hyytiä, P; Jerlhag, E; Landgren, S; Simms, JA, 2012) |
| "Treatment with sivelestat sodium hydrate also decreased serum neutrophil elastase activity." | 1.33 | [Survival by a young woman with malnutrition due to alcoholism and eating disorders and with acute respiratory distress syndrome due to severe pneumonia who showed increased serum neutrophil elastase activity]. ( Nakajima, H; Nakajima, S; Sawaguchi, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (22.22) | 18.7374 |
| 1990's | 4 (14.81) | 18.2507 |
| 2000's | 10 (37.04) | 29.6817 |
| 2010's | 7 (25.93) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Prisciandaro, JJ | 1 |
| Schacht, JP | 1 |
| Prescot, AP | 1 |
| Brenner, HM | 1 |
| Renshaw, PF | 1 |
| Brown, TR | 1 |
| Anton, RF | 1 |
| Suchankova, P | 1 |
| Steensland, P | 1 |
| Fredriksson, I | 1 |
| Engel, JA | 2 |
| Jerlhag, E | 2 |
| Harvey, RJ | 1 |
| Yee, BK | 1 |
| Gomez, JL | 1 |
| Cunningham, CL | 1 |
| Finn, DA | 1 |
| Young, EA | 1 |
| Helpenstell, LK | 1 |
| Schuette, LM | 1 |
| Fidler, TL | 1 |
| Kosten, TA | 1 |
| Ryabinin, AE | 1 |
| Alén, F | 1 |
| Santos, A | 1 |
| Moreno-Sanz, G | 1 |
| González-Cuevas, G | 1 |
| Giné, E | 1 |
| Franco-Ruiz, L | 1 |
| Navarro, M | 1 |
| López-Moreno, JA | 1 |
| Krystal, JH | 1 |
| Petrakis, IL | 1 |
| Limoncelli, D | 1 |
| Nappi, SK | 1 |
| Trevisan, L | 1 |
| Pittman, B | 1 |
| D'Souza, DC | 1 |
| Suckow, RF | 1 |
| Landgren, S | 1 |
| Simms, JA | 1 |
| Hyytiä, P | 1 |
| Bartlett, SE | 1 |
| Mariager, TP | 1 |
| Madsen, PV | 1 |
| Ebbehøj, NE | 1 |
| Schmidt, B | 1 |
| Juhl, A | 1 |
| SIEGEL, FL | 1 |
| ROACH, MK | 1 |
| POMEROY, LR | 1 |
| SPENCER, RP | 1 |
| BRODY, KR | 1 |
| LUTTERS, BM | 1 |
| Schumann, G | 1 |
| Rujescu, D | 1 |
| Kissling, C | 1 |
| Soyka, M | 2 |
| Dahmen, N | 1 |
| Preuss, UW | 2 |
| Wieman, S | 1 |
| Depner, M | 1 |
| Wellek, S | 1 |
| Lascorz, J | 1 |
| Bondy, B | 2 |
| Giegling, I | 1 |
| Anghelescu, I | 1 |
| Cowen, MS | 1 |
| Poustka, A | 1 |
| Spanagel, R | 3 |
| Mann, K | 2 |
| Henn, FA | 1 |
| Szegedi, A | 1 |
| Siggins, GR | 1 |
| Martin, G | 1 |
| Roberto, M | 1 |
| Nie, Z | 1 |
| Madamba, S | 1 |
| De Lecea, L | 1 |
| Koller, G | 1 |
| Zill, P | 1 |
| Ende, G | 1 |
| Welzel, H | 1 |
| Walter, S | 1 |
| Weber-Fahr, W | 1 |
| Diehl, A | 1 |
| Hermann, D | 1 |
| Heinz, A | 1 |
| Aliyev, NA | 2 |
| Aliyev, ZN | 2 |
| Nakajima, H | 1 |
| Sawaguchi, H | 1 |
| Nakajima, S | 1 |
| Vengeliene, V | 1 |
| Bilbao, A | 1 |
| Molander, A | 1 |
| Li, Z | 1 |
| Zharikova, A | 1 |
| Bastian, J | 1 |
| Esperon, L | 1 |
| Hebert, N | 1 |
| Mathes, C | 1 |
| Rowland, NE | 1 |
| Peris, J | 1 |
| Nath, R | 1 |
| Thind, SK | 1 |
| Murthy, MS | 1 |
| Talwar, HS | 1 |
| Farooqui, S | 1 |
| Aliguliyev, AR | 1 |
| Schofield, P | 1 |
| Darstein, M | 1 |
| Albrecht, C | 1 |
| López-Francos, L | 1 |
| Knörle, R | 1 |
| Hölter, SM | 1 |
| Feuerstein, TJ | 1 |
| Kharchenko, NK | 2 |
| Duplenko, PIu | 1 |
| Kovtun, TV | 1 |
| Stohniĭ, NA | 1 |
| Synyts'kyĭ, VM | 1 |
| Cooper, BR | 1 |
| Viik, K | 1 |
| Ferris, RM | 1 |
| White, HL | 1 |
| Mantero, O | 1 |
| Conti, F | 1 |
| Bertoli, L | 1 |
| Ball, GV | 1 |
| Sorensen, LB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Glycine and Oral D-Cycloserine in Alcoholic Patients and Healthy Subjects[NCT00635102] | 57 participants (Actual) | Interventional | 1997-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Alcohol Craving Scale (ACS) Subscale: Desire to drink: Self-report rating scale used to measure desire to drink alcohol (0 No desire to drink alcohol - 100 Definitely desire to drink alcohol) (NCT00635102)
Timeframe: 120 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 6.19 | 8 | 9.05 | 5.24 |
| Healthy Subjects | 1.30 | 1.667 | 2.08 | 2.08 |
Alcohol Craving Scale (ACS) Subscale: Desire to drink: Self-report rating scale used to measure desire to drink alcohol (0 No desire to drink alcohol - 100 Definitely desire to drink alcohol) (NCT00635102)
Timeframe: 60 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 6.5 | 9 | 10.48 | 5.71 |
| Healthy Subjects | 1.82 | 2.17 | 1.67 | 2.08 |
Alcohol Craving Scale (ACS) Subscale: Desire to drink: Self-report rating scale used to measure desire to drink alcohol (0 No desire to drink alcohol - 100 Definitely desire to drink alcohol) (NCT00635102)
Timeframe: 60 minutes prior to Glycine infusion
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 7.27 | 8.5 | 6.67 | 4.76 |
| Healthy Subjects | 2.61 | 1.67 | 3.04 | 1.25 |
Alcohol Craving Scale (ACS) Subscale: Desire to drink: Self-report rating scale used to measure desire to drink alcohol (0 No desire to drink alcohol - 100 Definitely desire to drink alcohol) (NCT00635102)
Timeframe: Baseline
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 7.62 | 9.5 | 5 | 7.62 |
| Healthy Subjects | 3.04 | 2.5 | 1.67 | 0 |
Alcohol Craving Scale (ACS) Subscale: Desire to drink: Self-report rating scale used to measure desire to drink alcohol (0 No desire to drink alcohol - 100 Definitely desire to drink alcohol) (NCT00635102)
Timeframe: 30 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 9.05 | 9 | 8 | 5.71 |
| Healthy Subjects | 1.82 | 2.17 | 2.5 | 2.08 |
Alcohol Craving Scale (ACS) Subscale: Discomfort: Self-report rating scale - subscale reflecting expected alcohol-related relief from discomfort (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: 120 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 8.57 | 9.5 | 9.05 | 6.19 |
| Healthy Subjects | 1.14 | 1.67 | 0.42 | 0.83 |
Alcohol Craving Scale (ACS) Subscale: Discomfort: Self-report rating scale - subscale reflecting expected alcohol-related relief from discomfort (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: 30 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 12.38 | 8.95 | 9.5 | 8.57 |
| Healthy Subjects | 1.82 | 1.74 | 0.42 | 0.42 |
Alcohol Craving Scale (ACS) Subscale: Discomfort: Self-report rating scale - subscale reflecting expected alcohol-related relief from discomfort (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: 60 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 6.5 | 10.5 | 9.05 | 6.19 |
| Healthy Subjects | 1.36 | 1.74 | 0.42 | 0.83 |
Alcohol Craving Scale (ACS) Subscale: Discomfort: Self-report rating scale - subscale reflecting expected alcohol-related relief from discomfort (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: 60 minutes prior to Glycine infusion
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 6.36 | 8.95 | 7.14 | 10.48 |
| Healthy Subjects | 1.30 | 1.25 | 0.44 | 0.42 |
Alcohol Craving Scale (ACS) Subscale: Discomfort: Self-report rating scale - subscale reflecting expected alcohol-related relief from discomfort (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: Baseline
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 8.1 | 12.5 | 7.73 | 8.10 |
| Healthy Subjects | 2.61 | 1.67 | 0.42 | 0.42 |
Alcohol Craving Scale (ACS) Subscale: Mood improvement : Self-report rating scale used to measure expected alcohol-related mood improvement (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: 120 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 6.19 | 7 | 8.57 | 7.62 |
| Healthy Subjects | 0.87 | 0.83 | 0.42 | 0.42 |
Alcohol Craving Scale (ACS) Subscale: Mood improvement : Self-report rating scale used to measure expected alcohol-related mood improvement (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: 30 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 11.43 | 8 | 10.5 | 6.67 |
| Healthy Subjects | 0.91 | 0.87 | 0.42 | 0.42 |
Alcohol Craving Scale (ACS) Subscale: Mood improvement : Self-report rating scale used to measure expected alcohol-related mood improvement (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: 60 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 5.5 | 8.5 | 8.1 | 6.67 |
| Healthy Subjects | 0.46 | 0.87 | 0.83 | 0.83 |
Alcohol Craving Scale (ACS) Subscale: Mood improvement : Self-report rating scale used to measure expected alcohol-related mood improvement (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: 60 minutes prior to Glycine infusion
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 7.73 | 8 | 7.62 | 6.19 |
| Healthy Subjects | 0.87 | 0.83 | 1.30 | 0.42 |
Alcohol Craving Scale (ACS) Subscale: Mood improvement : Self-report rating scale used to measure expected alcohol-related mood improvement (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: Baseline
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 6.67 | 10.5 | 6.82 | 8.10 |
| Healthy Subjects | 1.74 | 0.42 | 0.42 | 0 |
Alcohol Craving Scale (ACS) Subscale: Self-report rating scale used to measure reduced control of alcohol (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: 120 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 34.29 | 33.5 | 30.48 | 36.67 |
| Healthy Subjects | 98.26 | 99.17 | 99.17 | 99.17 |
Alcohol Craving Scale (ACS) Subscale: Self-report rating scale used to measure reduced control of alcohol (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: 30 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 32.86 | 36 | 36.5 | 36.67 |
| Healthy Subjects | 99.1 | 98.70 | 99.17 | 99.17 |
Alcohol Craving Scale (ACS) Subscale: Self-report rating scale used to measure reduced control of alcohol (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: 60 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 34 | 39.5 | 25.71 | 37.14 |
| Healthy Subjects | 99.1 | 99.13 | 99.17 | 99.17 |
Alcohol Craving Scale (ACS) Subscale: Self-report rating scale used to measure reduced control of alcohol (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: 60 minutes prior to Glycine infusion
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 30.46 | 40.5 | 36.67 | 42.86 |
| Healthy Subjects | 98.26 | 95 | 99.13 | 99.17 |
Alcohol Craving Scale (ACS) Subscale: Self-report rating scale used to measure reduced control of alcohol (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: Baseline
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 29.05 | 35.5 | 42.27 | 41.43 |
| Healthy Subjects | 93.48 | 94.58 | 99.17 | 98.75 |
Self-report rating scale used to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol (NCT00635102)
Timeframe: 60 minutes prior to Glycine infusion
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 6.23 | 6.6 | 7.24 | 4.57 |
| Healthy Subjects | 7.39 | 3.79 | 6.25 | 3.67 |
Self-report rating scale used to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol (NCT00635102)
Timeframe: 120 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 3.57 | 4.35 | 4 | 3.71 |
| Healthy Subjects | 4.13 | 1.67 | 3.04 | 1.25 |
Self-report rating scale used to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol (NCT00635102)
Timeframe: 30 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 7.14 | 5.8 | 5.2 | 4.62 |
| Healthy Subjects | 10.05 | 5.87 | 7.04 | 3.58 |
Self-report rating scale used to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol (NCT00635102)
Timeframe: 60 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 5.29 | 5.65 | 8.48 | 4.14 |
| Healthy Subjects | 9.64 | 5.83 | 8.54 | 2.54 |
Self-report rating scale used to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol (NCT00635102)
Timeframe: Baseline
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 3.41 | 3.3 | 3.57 | 5 |
| Healthy Subjects | 1.91 | 2.75 | 1.83 | 1.88 |
gordon diagnostic system is a continuous performance task (CPT) to measure distractibility - (A-Prime score range 0 minimum - 1 maximum - the higher number the better the performance) (NCT00635102)
Timeframe: 30 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 0.93 | 0.97 | 0.90 | 0.96 |
| Healthy Subjects | 0.1 | 0.1 | 0.1 | 0.1 |
gordon diagnostic system is a continuous performance task (CPT) to measure Vigilance - (A-Prime score range 0 minimum - 1 maximum - The higher number the better the performance) (NCT00635102)
Timeframe: 30 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 0.98 | 0.1 | 0.1 | 0.99 |
| Healthy Subjects | 0.1 | 0.1 | 0.1 | 0.1 |
Hopkins Verbal Learning Task (HVLT) - measures verbal memory and hippocampus function. (delay recall - 30 minutes after Trials 1-3 were given) (0 No words recalled - 12 all words recalled) (NCT00635102)
Timeframe: 90 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 5.1 | 7.75 | 6.29 | 8.25 |
| Healthy Subjects | 9.7 | 10.87 | 10.21 | 11.38 |
Hopkins Verbal Learning Task (HVLT) - measures verbal memory and hippocampus function. (Three immediate recall trials) (0 No words recalled - 12 all words recalled) (NCT00635102)
Timeframe: 60 minutes - Trial 1
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 5.29 | 6.05 | 5.48 | 5.95 |
| Healthy Subjects | 7.09 | 8.52 | 7.75 | 8.2 |
Hopkins Verbal Learning Task (HVLT) - measures verbal memory and hippocampus function. (Three immediate recall trials) (0 No words recalled - 12 all words recalled) (NCT00635102)
Timeframe: 60 minutes - Trial 2
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 7.67 | 8.45 | 7.1 | 8.67 |
| Healthy Subjects | 10.09 | 11.09 | 10.5 | 10.96 |
Hopkins Verbal Learning Task (HVLT) - measures verbal memory and hippocampus function. (Three immediate recall trials) (0 No words recalled - 12 all words recalled) (NCT00635102)
Timeframe: 60 minutes - Trial 3
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 8 | 9.2 | 8.48 | 9.24 |
| Healthy Subjects | 10.57 | 11.48 | 11.17 | 11.67 |
The Number of Drinks Scale asks subjects to report on the number of alcoholic drinks they felt they had consumed. (NCT00635102)
Timeframe: 120 minutes
| Intervention | Number of Drinks Felt Consumed (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 0 | 0.1 | 0.05 | 0 |
| Healthy Subjects | 0.13 | 0.21 | 0 | 0.04 |
The Number of Drinks Scale asks subjects to report on the number of alcoholic drinks they felt they had consumed. (NCT00635102)
Timeframe: 30 minutes
| Intervention | Number of Drinks Felt Consumed (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 0.38 | 0.20 | 0.38 | 0.24 |
| Healthy Subjects | 0.68 | 0.13 | 0.38 | 0.04 |
The Number of Drinks Scale asks subjects to report on the number of alcoholic drinks they felt they had consumed. (NCT00635102)
Timeframe: 60 minutes
| Intervention | Number of Drinks Felt Consumed (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 0.05 | 0.5 | 0.86 | 0.05 |
| Healthy Subjects | 1.24 | 0.4 | 0.83 | 0.2 |
The Number of Drinks Scale asks subjects to report on the number of alcoholic drinks they felt they had consumed. (NCT00635102)
Timeframe: 60 minutes prior to Glycine infusion
| Intervention | drinks felt consumed (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 0.50 | 0.30 | 0.24 | 0.05 |
| Healthy Subjects | 0.70 | 0.25 | 0.75 | 0.22 |
Visual Analog Scales (VAS): Self-report rating scale used to measure high (0 not at all - 7 extremely) (NCT00635102)
Timeframe: 120 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 0.8 | 0.55 | 0.76 | 0.24 |
| Healthy Subjects | 0.35 | 0.21 | 0.29 | 0.25 |
Visual Analog Scales (VAS): Self-report rating scale used to measure high (0 not at all - 7 extremely) (NCT00635102)
Timeframe: 30 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 0.48 | 0.65 | 0.48 | 0.52 |
| Healthy Subjects | 1.05 | 0.30 | 0.79 | 0.25 |
Visual Analog Scales (VAS): Self-report rating scale used to measure high (0 not at all - 7 extremely) (NCT00635102)
Timeframe: 60 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 0.52 | 0.8 | 0.6 | 0.19 |
| Healthy Subjects | 0.91 | 0.22 | 0.71 | 0.17 |
Visual Analog Scales (VAS): Self-report rating scale used to measure high (0 not at all - 7 extremely) (NCT00635102)
Timeframe: 60 minutes prior to Glycine infusion
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 0.64 | 0.68 | 0.48 | 0.38 |
| Healthy Subjects | 0.82 | 0.33 | 0.96 | 0.61 |
Visual Analog Scales (VAS): Self-report rating scale used to measure high (0 not at all - 7 extremely) (NCT00635102)
Timeframe: Baseline
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 0.32 | 0.5 | 0.76 | 0.48 |
| Healthy Subjects | 0.22 | 0.22 | 0.25 | 0.25 |
Visual Analog Scales of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol -7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol (NCT00635102)
Timeframe: Baseline
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 0.18 | 0.25 | 0.10 | 0.24 |
| Healthy Subjects | 0.05 | 0.04 | 0.04 | 0 |
Visual Analog Scales of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol -7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol (NCT00635102)
Timeframe: 120 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 0.43 | 0.3 | 0.57 | 0.10 |
| Healthy Subjects | 0.41 | 0.09 | 0.29 | 0.33 |
Visual Analog Scales of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol -7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol (NCT00635102)
Timeframe: 30 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 0.57 | 0.60 | 1.05 | 0.43 |
| Healthy Subjects | 1.81 | 0.71 | 1.21 | 0.13 |
Visual Analog Scales of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol -7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol (NCT00635102)
Timeframe: 60 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 0.67 | 0.75 | 0.81 | 0.24 |
| Healthy Subjects | 1.81 | 0.70 | 1.46 | 0.13 |
Visual Analog Scales of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol -7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol (NCT00635102)
Timeframe: 60 minutes prior to Glycine infusion
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
| Alcoholic Subjects | 0.77 | 0.65 | 0.48 | 0.43 |
| Healthy Subjects | 1.41 | 0.67 | 1.17 | .025 |
4 reviews available for glycine and Alcoholism
| Article | Year |
|---|---|
Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain.
Topics: Alcoholism; Animals; Drugs, Investigational; Glycine; Glycine Plasma Membrane Transport Proteins; Hu | 2013 |
Glutamatergic transmission in opiate and alcohol dependence.
Topics: Alcoholism; Amygdala; Animals; Ethanol; Glutamates; Glycine; Humans; Morphine Dependence; Neurons; N | 2003 |
Neuropharmacology of alcohol addiction.
Topics: Alcoholism; Animals; Behavior, Addictive; Cannabinoids; Central Nervous System Agents; Corticotropin | 2008 |
Molecular aspects of idiopathic urolithiasis.
Topics: Adult; Alcoholism; Animals; Calcium; Child; Child, Preschool; Dietary Carbohydrates; Dietary Fats; D | 1984 |
3 trials available for glycine and Alcoholism
| Article | Year |
|---|---|
Characterization of the interactive effects of glycine and D-cycloserine in men: further evidence for enhanced NMDA receptor function associated with human alcohol dependence.
Topics: Adult; Alcoholism; Amnesia; Antimetabolites; Arousal; Chromatography, Liquid; Cognition; Cycloserine | 2011 |
Application of glycine in acute alcohol hallucinosis.
Topics: Administration, Sublingual; Adult; Alcoholism; Double-Blind Method; Drug Administration Schedule; Gl | 2005 |
[The effect of medikhronal on the psychophysiological and metabolic processes in alcoholism].
Topics: Adult; Alcohol Deterrents; Alcoholism; Brain; Drug Combinations; Electroencephalography; Formates; G | 2000 |
20 other studies available for glycine and Alcoholism
| Article | Year |
|---|---|
Evidence for a unique association between fronto-cortical glycine levels and recent heavy drinking in treatment naïve individuals with alcohol use disorder.
Topics: Adult; Alcoholism; Binge Drinking; Female; Frontal Lobe; Glutamic Acid; Glycine; Humans; Male; Proto | 2019 |
Ghrelin receptor (GHS-R1A) antagonism suppresses both alcohol consumption and the alcohol deprivation effect in rats following long-term voluntary alcohol consumption.
Topics: Administration, Oral; Alcohol Drinking; Alcoholism; Animals; CpG Islands; DNA Methylation; Gene Expr | 2013 |
Differential effects of ghrelin antagonists on alcohol drinking and reinforcement in mouse and rat models of alcohol dependence.
Topics: Alcohol Drinking; Alcoholism; Animals; Central Nervous System Agents; Conditioning, Operant; Disease | 2015 |
Cannabinoid-induced increase in relapse-like drinking is prevented by the blockade of the glycine-binding site of N-methyl-D-aspartate receptors.
Topics: Alcohol Drinking; Alcoholism; Animals; Benzoxazines; Binding Sites; Cannabinoids; Conditioning, Oper | 2009 |
Ghrelin receptor (GHS-R1A) antagonism suppresses both operant alcohol self-administration and high alcohol consumption in rats.
Topics: Alcohol Drinking; Alcoholism; Analysis of Variance; Animals; Central Nervous System Depressants; Cho | 2012 |
Severe adverse effects related to dermal exposure to a glyphosate-surfactant herbicide.
Topics: Adrenal Cortex Hormones; Adult; Alcoholism; Alopecia; Analgesics; Blister; Burns, Chemical; Fingers; | 2013 |
PLASMA AMINO ACID PATTERNS IN ALCOHOLISM: THE EFFECTS OF ETHANOL LOADING.
Topics: Alanine; Alcoholism; Amino Acids; Autoanalysis; Biomedical Research; Blood; Ethanol; Genetics, Medic | 1964 |
SOME EFFECTS OF ETHANOL ON THE GASTROINTESTINAL TRACT.
Topics: Alcohol Oxidoreductases; Alcoholism; Colon; Cricetinae; Ethanol; Gastrointestinal Tract; Glycine; Hi | 1964 |
Analysis of genetic variations of protein tyrosine kinase fyn and their association with alcohol dependence in two independent cohorts.
Topics: 5' Untranslated Regions; Adult; Alanine; Alcoholism; Case-Control Studies; Chi-Square Distribution; | 2003 |
Alcoholism-related phenotypes and genetic variants of the CB1 receptor.
Topics: Adult; Alanine; Alcoholism; Analysis of Variance; Case-Control Studies; Chitinases; Delirium; Drosop | 2003 |
Monitoring the effects of chronic alcohol consumption and abstinence on brain metabolism: a longitudinal proton magnetic resonance spectroscopy study.
Topics: Adult; Aged; Alcoholism; Aspartic Acid; Brain Chemistry; Creatine; Female; Functional Laterality; Gl | 2005 |
[Survival by a young woman with malnutrition due to alcoholism and eating disorders and with acute respiratory distress syndrome due to severe pneumonia who showed increased serum neutrophil elastase activity].
Topics: Adult; Alcoholism; Feeding and Eating Disorders; Female; Glycine; Humans; Leukocyte Elastase; Malnut | 2006 |
High temporal resolution of amino acid levels in rat nucleus accumbens during operant ethanol self-administration: involvement of elevated glycine in anticipation.
Topics: Alcohol-Induced Disorders, Nervous System; Alcoholism; Amino Acids; Animals; Central Nervous System | 2008 |
Amino acid neurotransmitters in alcohol withdrawal.
Topics: Adult; Alcohol Withdrawal Delirium; Alcoholism; Amino Acids; Aspartic Acid; gamma-Aminobutyric Acid; | 1994 |
Glycine: the other inhibitory neurotransmitter.
Topics: Alcoholism; Animals; DNA Mutational Analysis; Drug Synergism; Ethanol; Glycine; Humans; Mice; Mice, | 1996 |
Release and accumulation of neurotransmitters in the rat brain: acute effects of ethanol in vitro and effects of long-term voluntary ethanol intake.
Topics: Acetylcholine; Alcoholism; Animals; Brain; Caudate Nucleus; Ethanol; gamma-Aminobutyric Acid; Glycin | 1998 |
[The effect of medikhronal on the biogenic amine level in the brain structures and blood of animals with alcohol dependence].
Topics: Alcohol Deterrents; Alcoholic Intoxication; Alcoholism; Animals; Biogenic Amines; Brain; Brain Chemi | 1999 |
Antagonism of the enhanced susceptibility to audiogenic seizures during alcohol withdrawal in the rat by gamma-aminobutyric acid (GABA) and "GABA-mimetic" agents.
Topics: 4-Aminobutyrate Transaminase; Acoustic Stimulation; Alcoholism; Aminobutyrates; Animals; Binding, Co | 1979 |
[Alpha-mercaptopropionylglycine (Thiola) in the treatment of chronic liver diseases with special reference to the effects of the drug on the index of prognosis in alcoholic cirrhosis].
Topics: Alcoholism; Amino Acids, Sulfur; Biopsy; Drug Evaluation; Glycine; Humans; Liver; Liver Cirrhosis; L | 1974 |
Pathogenesis of hyperuricemia in saturnine gout.
Topics: Adult; Alcoholic Beverages; Alcoholism; Carbon Isotopes; Creatinine; Diet; Food Contamination; Glyci | 1969 |